- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00977119
Investigation of Genetic Determinants of Capecitabine Toxicity
April 26, 2023 updated by: University of Chicago
The purpose of this study is to identify possible genetic polymorphisms that contribute to specific toxicities associated with capecitabine (hand-foot syndrome, diarrhea, and neutropenia).
Additionally, this study will look at gene polymorphisms in patients experiencing the toxicities of interest, the frequency of polymorphisms and differences in drug metabolism.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
240
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama - Birmingham
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Georgetown University
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
Evanston, Illinois, United States, 60201
- NorthShore University Healthsystem
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Cancer Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina - Chapel Hill
-
Durham, North Carolina, United States, 27708
- Duke University
-
-
Tennessee
-
Nashville, Tennessee, United States, 73232
- Vanderbilt University Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- M.D. Anderson Cancer Center
-
Houston, Texas, United States, 77030
- Baylor University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients receiving treatment with capecitabine for breast cancer at a participating academic medical center.
Description
Inclusion Criteria:
- women with breast cancer in whom single agent capecitabine therapy is being considered
- aged 18 years and older
Exclusion Criteria:
- patients who have previously received capecitabine are excluded
- patients cannot be receiving capecitabine in combination with another cancer chemotherapy; concurrent use of trastuzumab is not permitted; concurrent use of zoledronic acid is allowed
- serum albumin less than 3.0 g/dL within the last 30 days
- creatinine clearance (CrCL) or glomerular filtration rate (GFR) less than 60 mL/min [/body surface area (BSA)] (within the last 30 days)
- inability to understand and give informed consent to participate
- patients with a history of inflammatory bowel disease requiring therapy or patients with chronic diarrhea syndromes or paralytic ileus
- patients with prior or concurrent pelvic irradiation
- patients who use an ostomy for fecal excretion
- there is no limit on the number of prior chemotherapies; the decision to use capecitabine is determined solely by the treating physician
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Capecitabine
Women with breast cancer receiving capecitabine as treatment for their breast cancer.
|
Paper or telephone questionnaire to report specific side-effects associated with their breast cancer treatment weekly
Blood samples for research on DNA before starting treatment and after 4 cycles of treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Genetic variants of toxicity
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to toxicity based on genetics
Time Frame: 2 years
|
2 years
|
Multiple genetic variants as predictors
Time Frame: 2 years
|
2 years
|
Genome-wide association (potential)
Time Frame: 2 years
|
2 years
|
Correlative sample collection
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Peter H O'Donnell, MD, University of Chicago
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2009
Primary Completion (Anticipated)
May 15, 2024
Study Completion (Anticipated)
May 15, 2024
Study Registration Dates
First Submitted
September 14, 2009
First Submitted That Met QC Criteria
September 14, 2009
First Posted (Estimate)
September 15, 2009
Study Record Updates
Last Update Posted (Actual)
April 28, 2023
Last Update Submitted That Met QC Criteria
April 26, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 09-056-B
- TBCRC 015 (Other Identifier: Translational Breast Cancer Reseach Consortium)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Side-effect questionnaires
-
Germans Trias i Pujol HospitalCompletedAdverse Drug Reaction
-
University of British ColumbiaBoston Scientific CorporationUnknownEssential Tremor | Deep Brain Stimulation | Directional LeadCanada
-
White River Junction Veterans Affairs Medical CenterAttorney General Consumer & Prescriber Education GrantCompleted
-
The University of Hong KongActive, not recruitingPostoperative PainHong Kong
-
Philipps University Marburg Medical CenterUniversitätsklinikum Hamburg-Eppendorf; University of Hamburg-EppendorfUnknownFemale Breast CancerGermany
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinCompletedPost Operative PainUnited States
-
Peking University Third HospitalBeihang UniversityCompletedKnee Ligament; LaxityChina
-
Yonsei UniversityUnknownHCC | Pancreatic Cancer | Cholangiocarcinoma | Gallbladder Cancer | AOV CancerKorea, Republic of
-
Technische Universitaet BraunschweigGerman Research FoundationCompletedEnhancing Couples Coping
-
Tianjin Medical University Cancer Institute and...RecruitingEpiphora Due to Insufficient Drainage, Left Side | Epiphora Due to Insufficient Drainage, Right SideChina